The reduced immune infiltration in MYCN-amplified tumors, linked to poor survival outcomes, underscores the role of an immunosuppressive microenvironment in neuroblastoma progression and highlights immune modulation as a potential therapeutic strategy for high-risk patients [10,12,32]. This evidence concerns the gene MYCN and neuroblastoma.